Treatment of Acutely Decompensated Heart Failure

Teerlink, John R.

doi:10.1002/9780470669402.ch14

Cited by 3 publications

(2 citation statements)

References 99 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While not yet incorporated into routine clinical practice to the degree of serum biomarkers such as NT-ProBNP, BIA has potential to augment clinician judgment with regards to volume assessment [ 43 , 45 ]. Prospective, controlled such as the SCALE-HF trials using BIA to guide clinical decision making in HF patients are currently underway [ 46 , 47 ]. This noninvasive, objective modality of evaluation holds considerable promise in improving clinician ability to accurately ascertain congestion status.…”

Section: Laboratory Abnormalities and Biometric Evaluationmentioning

confidence: 99%

Assessment of Volume Status in Hospitalized Patients With Chronic Heart Failure

2023

View full text Add to dashboard Cite

Assessment of volume status in hospitalized patients with heart failure is a critically important diagnostic skill that clinicians utilize frequently. However, accurate assessment is challenging and there is often significant inter-provider disagreement. This review serves as an appraisal of current methods of volume assessment amongst different categories of evaluation including patient history, physical exam, laboratory analysis, imaging, and invasive procedures. Within each category, this review highlights methods that are particularly sensitive or specific, or those that carry impactful positive or negative likelihood ratios. Utilization of the information that this review provides will allow clinicians to determine volume status of hospitalized heart failure patients more accurately and more precisely in order to provide appropriate and effective therapies.

show abstract

Section: Laboratory Abnormalities and Biometric Evaluationmentioning

confidence: 99%

Assessment of Volume Status in Hospitalized Patients With Chronic Heart Failure

2023

View full text Add to dashboard Cite

show abstract

“…In a clinical registry of 187,565 cases of AHF, at the time of admission, approximately 50% of patients had SBP >140 mmHg and only 2% of patients with SBP <90 mmHg. 2 Although such varied ways of classifying AHF signify the diversity of its clinicopathophysiology, a number of the clinical trials in AHF over the last few decades have used unselected are approximately 7% and 10%, respectively. 1-3 After discharge, 180-day and 1-year mortality is 15% and 35-40%, respectively.…”

mentioning

confidence: 99%

Therapeutic Effects of Serelaxin in Acute Heart Failure

Hewitson

Nguyen

et al. 2014

Circ J

View full text Add to dashboard Cite

Serelaxin: a potential new drug for the treatment of acute heart failure

Neverova

Teerlink

2014

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Recent clinical trials of serelaxin (Pre-RELAX-AHF; RELAX-AHF) have provided a new hope in AHF. They have demonstrated significant serelaxin-related improvement in heart failure symptoms, length of hospital stay as well as mortality reduction in AHF patients. These findings were in the context of early administration in the course of AHF presentation in patients with normal or high blood pressures, thus highlighting the drug's strengths based on its molecular mechanisms of action. Overall, serelaxin is a promising therapy, and further studies aimed at reproducibility of prior results, safety and hemodynamic effects of serelaxin, as well as investigation of the molecular reasons for such effects are currently under way.

show abstract

Treatment of Acutely Decompensated Heart Failure

Cited by 3 publications

References 99 publications

Assessment of Volume Status in Hospitalized Patients With Chronic Heart Failure

Assessment of Volume Status in Hospitalized Patients With Chronic Heart Failure

Therapeutic Effects of Serelaxin in Acute Heart Failure

Serelaxin: a potential new drug for the treatment of acute heart failure

Contact Info

Product

Resources

About